{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-250757","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.050000+00:00","generated_at":"2026-05-17T02:11:27.242069+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Intellia pauses dosing in Phase 3 MAGNITUDE trials after Grade 4 liver event in one patient","bullets":["Patient dosed on Sept 30, 2025, experienced Grade 4 liver transaminases and increased total bilirubin on Oct 24.","Patient hospitalized and receiving medical intervention; Intellia consulting experts and regulators.","Pause affects both MAGNITUDE (ATTR-CM, >650 enrolled) and MAGNITUDE-2 (ATTR-PN, 47 enrolled) trials.","Over 450 patients estimated to have been dosed with nex-z across both trials to date.","Conference call scheduled at 8:30 a.m. ET today to discuss the update."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-250757","json":"https://secwatch.observer/filing/0001193125-25-250757.json","markdown":"https://secwatch.observer/filing/0001193125-25-250757.md","text":"https://secwatch.observer/filing/0001193125-25-250757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525250757/0001193125-25-250757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525250757/d44351d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:11:27.242069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}